Post Marketing Surveillance, 7 (1993) 375–376
© 1993 Elsevier Science Publishers B.V. All rights reserved 0269-2333/93/$06.00

AUTHOR INDEX

Abenhaim, L., Moride, Y., Risk and assessment, 139
Alroy, G., see Krivoy, N., 345

Barberger-Gateau, P., see Fourrier, A., 291
Bassin, L.G., see Funch, D., 283
Bégaud, B., see Fourrier, A., 291
Bégaud, B., see Haramburu, F., 27
Bégaud, B., Miremont, G., Tubert-Bitter, P., Expected number of adverse reactions in a sample, 99
Bégaud, B., Péré, J.-C., Miremont, G., Estimation of the denominator in spontaneous reporting, 51
Bégaud, B., Tubert-Bitter, P., "If nothing goes wrong, is everything all right?", 89
Bégaud, B., see Tubert-Bitter, P., 71, 119
Bengtsson, B.-O., Retrospective case-control studies of psychiatric patients with or without a hypersensitivity reaction during zimeldine therapy, 315
Brickley, M.G., see Funch, D., 283

Capaul, R., Maibach, R., Kuenzi, U.P., Egli, A., Wymann, R., Galeazzi, R.L., Neftel, K.A., Mueller, U., Hoigné, R., Atopy, bronchial asthma and previous adverse drug reactions (ADRs): risk factors for ADRs?, 331
Chaslerie, A., see Fourrier, A., 291
Crawley, J.A., see Funch, D., 283

Dartigues, J.F., see Fourrier, A., 291
Dequae, L., see Fourrier, A., 291
Dreyer, N.A., see Funch, D., 283

Egli, A., see Capaul, R., 331

Fourrier, A., Dequae, L., Chaslerie, A., Barberger-Gateau, P., Bégaud, B., Dartigues, J.F., Sociodemographic characteristics and polypharmacy in elderly people: data from the PAQUID study, 291
Fourrier, A., see Haramburu, F., 27
Fourrier, A., Péré, J.-C., Measurement of frequency in pharmacovigilance, 21
Funch, D., Dreyer, N.A., Bassin, L.G., Crawley, J.A., Brickley, M.G., Walker, A.M., The validity of case reports in a pharmacoepidemiologic study, 283

Galeazzi, R.L., see Capaul, R., 331
Ganesh, V., Malik, N., Lewis, R., Iffy, L., Corticosteroid-induced fetal compromise: a case report, 309

Hale, W.E., see Stewart, R.B., 299
Haramburu, F., Estimation of underreporting, 39
Haramburu, F., Fourrier, A., Péré, J.-C., Bégaud, B., Estimation of the numerator in spontaneous reporting, 27
Hoigné, R., see Capaul, R., 331

Iffy, L., see Ganesh, V., 309

Joannidès, R., see Moore, N., 355

Krivoy, N., Alroy, G., Exposure to cardiovascular medications during hospital care and discharge recommendations, 345
Kuenzi, U.P., see Capaul, R., 331

Lewis, R., see Ganesh, V., 309

Maibach, R., see Capaul, R., 331
Malik, N., see Ganesh, V., 309
Marks, I., Can benefits and costs be measured in a sensible and realistic way?, 271
Marks, R.G., see Stewart, R.B., 299
Masson, H., see Moore, N., 355

May, F.E., see Stewart, R.B., 299
Miremont, G., see Bégaud, B., 51, 99
Moore, N., Masson, H., Noblet, C., Joannidès, R., What medicines do patients really take? A comparison of free form vs. oriented questionnaires, 355
Moride, Y., see Abenhaim, L., 139
Mueller, U., see Capaul, R., 331

Neftel, K.A., see Capaul, R., 331
Neutel, C.I., A new, "user-friendly" terminology for confounding by indication in the study of adverse drug reactions, 363
Noblet, C., see Moore, N., 355

Péré, J.-C., see Bégaud, B., 51
Péré, J.-C., see Fourrier, A., 21
Péré, J.-C., see Haramburu, F., 27

Stewart, R.B., Marks, R.G., May, F.E., Hale, W.E., Hypolipidemic drug use in an ambulatory elderly population, 299

Tubert-Bitter, P., Modelling in pharmacovigilance, 151
Tubert-Bitter, P., see Bégaud, B., 89, 99
Tubert-Bitter, P., Bégaud, B., Confidence intervals in pharmacovigilance, 71
Tubert-Bitter, P., Bégaud, B., Comparing safety of drugs, 119

Walker, A.M., see Funch, D., 283
Wymann, R., see Capaul, R., 331